Table 3.
Survival for AJCC 8th edition TNM and TNnM staging systems for patients aged ≥ 55 years with papillary thyroid cancer.
| Classification System | Criteria | No. (%) of Patients | 10-year PTCSS, % | HR (95% CI) a |
|---|---|---|---|---|
| AJCC 8th edition TNM stage | ||||
| I | T1-2N0M0 | 2,733 (55) | 98.83 | 1 (Reference) |
| II | T1-2N1M0 T3, any N, M0 |
1,526 (30.7) | 93.49 | 5.85 (3.81–9.00) |
| III | T4a, any N, M0 | 321 (6.5) | 71.21 | 22.30 (14.41–34.49) |
| IVA | T4b, any N, M0 | 114 (2.3) | 72.95 | 24.60 (14.73–41.05) |
| IVB | Any T, any N, M1 | 277 (5.6) | 58.52 | 37.78 (24.50–58.26) |
| TNnM stage | ||||
| I | T1-2N0nM0 or T1N1nM0 | 3,388 (68.2) | 98.59 | 1 (Reference) |
| II | T3N0nM0 or T2N1nM0 or T1-2N2nM0 |
719 (14.5) | 92.2 | 5.95 (4.01–8.86) |
| III | T4N0nM0 or T3N1nM0 | 215 (4.3) | 83.26 | 11.22 (7.22–17.44) |
| IVA | T4N1nM0 or T3N2nM0 | 265 (5.3) | 75.24 | 17.67 (11.73–26.60) |
| IVB | T4N2nM0 or any T, any Nn, M1 | 384 (7.7) | 56.73 | 33.45 (23.42–47.78) |
PTCSS, papillary thyroid cancer-specific survival; Nn, metastatic node number; N0n, no evidence of metastatic nodes; N1n, 1-4 metastatic nodes; N2n, > 4 metastatic nodes; AJCC, American Joint Committee on Cancer; HR, hazards ratio; CI, confidence interval.
a
HRs were generated from 2 different multivariable Cox proportional hazards models based on the proposed TNnM and current TNM staging system. Both models were adjusted for patient age, sex, race, surgery, radioactive iodine use, and lymph node density.